Dr. Patrick Vollmer is an award-winning author, international speaker, and clinical researcher for the new developments of ophthalmic drugs. He specializes in comprehensive eye exams, contact lenses, eye emergencies/eye trauma and ocular disease. Dr. Vollmer holds a particular interest in diagnosing and customizing individual treatment plans for dry eye.

He is passionate about diabetic and hypertensive eye disease, glaucoma, co-management of systemic diseases, pharmacology, macular degeneration, and neuro-ophthalmic pathology. In order to take the very best care of your eyes, the clinic is equipped with the most cutting edge medical technologies found in the industry to date.

 

  • Top-300 Innovators in Optometry- Primary Care Optometry News, Healio

  • Top 50 Up-and-Coming Practitioners/Researchers in the United States- Primary Care Optometry News, Healio

  • Undergraduate- Appalachian State University, Boone, NC

  • Doctorate- Indiana University, Bloomington, IN

  • Internship- Charlotte Eye, Ear, Nose and Throat Associates, Charlotte, NC 

  • Residency- (Hospital) William Jennings Bryan Dorn VA Medical Center, Columbia, SC

  • Ophthalmic Assessments of Signs and Symptoms of Dry Eye in Patients Suffering from Self-Reported or Clinician Diagnosed Dry Eye Disease
  • A Phase 3, Multi-Centered, Randomized, Double-Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of SkQ1 Ophthalmic Solution in the Environment and During Challenge in the Controlled Adverse Environment (CAE) Model for the Treatment of Dry Eye Syndrome
  •  The RENEW Trial: A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Adaptive Phase 3 Clinical Trial to Assess the Safety and Efficacy of Reproxalap 0.25% Ophthalmic Solution Compared to Vehicle in Subjects with Dry Eye Disease
  • A Phase 3, Multicenter, Randomized, Double-Masked, Placebo-Controlled Clinical Study Evaluating the Efficacy and Safety of 0.25% HL036 Ophthalmic Solution Compared to Placebo in Subjects with Dry Eye
  • A Multi-Center, Double-Masked, Randomized, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of Dupilumab in Patients with Atopic Keratoconjunctivitis (AKC) 
  • A Multi-Centered, Randomized, Double-Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solutions for the Treatment of Dry Eye Using the Controlled Adverse Environmental (CAE) Model (ARISE-3)
  • Review of Optometry: 2019 Clinical Guide to Ophthalmic Drugs

  • Review of Optometry: 2018 Clinical Guide to Ophthalmic Drugs

  • Review of Optometry: 2017 Clinical Guide to Ophthalmic Drugs

  • Melton, Thomas, and Vollmer’s 21st Century Perspective on Glaucoma Patient Care

  • Chronic Myeloid Leukemic Infiltrative Retinopathy, AAOPT, October 2015

  • Non-Hodgkin’s Lymphoma Metastasis to the Right Lateral Rectus, SECO, February 2016

  • Optic Neuritis as an Initial Presentation in the Setting of Multiple Sclerosis, SCO, June 2016

  • Herpes Zoster Ophthalmicus, October 2016

  • Fellow of the American Academy of Optometry (FAAO)

  • American Optometric Association (AOA)

  • North Carolina Optometric Society (NCOS)

  • Uptown Shelby Association Board of Directors 

  • Cleveland County Rotary Club Member

  • Business Network International (Shelby)

Quick Profile

Name: Patrick Vollmer, OD, FAAO

Address: 222 N. Lafayette St., Suite 12
Phone: 704-487-4099
Recent Publication